Art. 6 Commission Regulation (EC) No 507/2006 of 29 March 2006 on the conditional marketing aut…

Renewal

In forcesince 29 Mar 2006cited 6×
1.

After its period of validity of one year the conditional marketing authorisation may be renewed annually.

2.

The application for renewal shall be submitted to the Agency at least six months before the expiry of the conditional marketing authorisation, together with an interim report on the fulfilment of the specific obligations to which it is subject.

3.

The Committee shall assess the application for a renewal, on the basis that the risk-benefit balance is to be confirmed, taking into account the specific obligations contained in the authorisation and the timeframe for their fulfilment, and shall formulate an opinion as to whether the specific obligations or their timeframes need to be retained or modified. The Agency shall ensure that the opinion of the Committee is given within 90 days following receipt of a valid renewal application. That opinion shall be made publicly available.

4.

Once a renewal application has been submitted in accordance with paragraph 2, the conditional marketing authorisation shall remain valid until a decision is adopted by the Commission in accordance with Article 10 of Regulation (EC) No 726/2004.

  • Ordonnance du président du Tribunal du 20 juillet 2016. PTC Therapeutics International Ltd contre Agence européenne des médicaments.Decision

    … 24, 26, 57(1), point (1), 57(2), 76 and 80 of Regulation No 726/2004, Article 4(7) of Regulation No 141/2000 and Articles 5(3), 6(3) and 8 of Regulation No 507/2006 — establish a specific set of rules on transparency and confidentiality, …

    20 Jul 2016 · 62015TO0718(02)

  • Order of the Vice-President of the Court of 1 March 2017. European Medicines Agency (EMA) v PTC Therapeutics International Ltd.Decision

    In the first place, all documents submitted in connection with an MA application and, in particular, clinical and non-clinical studies, such as the report at issue, should enjoy a general presumption of confidentiality under Regulation No …

    1 Mar 2017 · 62016CO0513

  • Judgment of the General Court (Second Chamber) of 5 February 2018. PTC Therapeutics International Ltd v European Medicines Agency.Decision

    [As rectified by order of 27 April 2018] As regards Regulation No 507/2006, its legal basis being Regulation No 726/2004, that also reflects the legislature’s intention that the MA procedure should be transparent. In addition, the …

    5 Feb 2018 · 62015TJ0718

  • Order of the President of the General Court of 26 November 2024. Advanz Pharma Ltd v European Commission.Decision

    While the review procedure was still ongoing, on 21 May 2024 the applicant submitted an application for renewal of the conditional marketing authorisation for Ocaliva pursuant to Article 6(2) of Commission Regulation (EC) No 507/2006 of 29 …

    26 Nov 2024 · 62024TO0455(01)

  • Arrêt du Tribunal (cinquième chambre) du 23 septembre 2026 (Extraits). Advanz Pharma Ltd contre Commission européenne.Decision

    Under Article 6 of Regulation No 507/2006: ‘1. After its period of validity of one year the conditional marketing authorisation may be renewed annually. 2. The application for renewal shall be submitted to the [European Medicines Agency] …

    23 Sep 2026 · 62024TJ0455

  • Conseil d'État, , 24/09/2021, 456543, Inédit au recueil LebonDecision

    … conditionnelles délivrées pour trois vaccins n'auraient pas été menées conformément aux dispositions de l'article 6 du règlement (CE) n° 507/2006 de la Commission du 29 mars 2006 relatif à l'autorisation de mise sur le marché …

    24 Sep 2021 · CETATEXT000044316249